Physician, chemist and biotech entrepreneur, Désiré Collen acquired an international reputation for his role in the development of recombinant t-PA(rt-PA), a life-saving drug that treats blood clots.
Collen was affiliated with KU Leuven until his retirement in 2008. He took on the chairmanship of ThromboGenics (now Oxurion), a position that he held until 2013.
In 2015 Désiré Collen founded Fund+ NV. Fund+ is an open-ended fund interested in innovative life science companies with a focus on Belgium. Fund+ wants to contribute to the development of a leadership position in the life sciences sector and generate a beneficial societal impact.